A P Mazar

Author PubWeight™ 13.06^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.	J Biol Chem	2000	1.31
2	Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.	J Biol Chem	1992	1.28
3	The role of the plasminogen activation system in angiogenesis and metastasis.	Surg Oncol Clin N Am	2001	1.20
4	Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.	Br J Cancer	2006	1.20
5	A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.	Proc Natl Acad Sci U S A	2000	1.09
6	Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224).	Br J Cancer	2008	1.01
7	A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo.	FASEB J	2000	1.01
8	A practical method for uniform isotopic labeling of recombinant proteins in mammalian cells.	Biochemistry	1992	0.98
9	Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.	Biochemistry	1994	0.91
10	Fibrin turnover in lung inflammation and neoplasia.	Am J Respir Crit Care Med	2001	0.91
11	Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).	Int J Cancer	1995	0.88
12	uPA and uPAR contribute to NK cell invasion through the extracellular matrix.	Anticancer Res	2001	0.80
13	Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase.	J Cell Physiol	1997	0.80